Literature DB >> 30996509

Optical Properties of Meloxicam in the Far-Infrared Spectral Region.

Yusuf Samet Aytekin1, Mustafa Köktürk2, Adam Zaczek3, Timothy M Korter3, Edwin J Heilweil4, Okan Esenturk1.   

Abstract

One of the most commonly used nonsteroidal anti-inflammatory active pharmaceutical ingredient called Meloxicam has been characterized spectroscopically both by Terahertz (THz) time domain spectroscopy (THz-TDS) and by Fourier Transform Infrared (FTIR) spectroscopy in far-IR regions of electromagnetic spectrum; 0.2 THz to 20 THz. While many relatively sharp features are observed in the far-IR range between 2 THz to 20 THz as expected for being an organic substance, very distinct and relatively strong absorption bands are also observed at 1.00, 1.66, 2.07 and 2.57 THz in the THz range. These well separated, defined, and fairly strong spectral features can be used for discrimination and quantification of Meloxicam in drug analysis. Frequency dependent refractive index of the drug was determined in a range of 0.2 THz and 2.7 THz, where an almost constant index was observed with an average index of 1.75. Powder XRD, and solid-state Density Functional Theory (SS-DFT) calculations were utilized to determine the crystalline form of the Meloxicam sample in its enolic crystalline form. Single molecule DFT calculations were also performed in all four possible structures of Meloxicam. In addition, the capability of THz waves transmission through common packaging materials is demonstrated for possibility of future on-site analysis. The results suggest that drug analysis will be possible to perform not only at every stage of manufacturing without destruction but also directly at the shelf of a market after development of portable THz technologies.

Entities:  

Keywords:  API characterization; THz-TDS; active pharmaceutical ingredients (API); infrared spectroscopy

Year:  2018        PMID: 30996509      PMCID: PMC6463309          DOI: 10.1016/j.chemphys.2018.04.022

Source DB:  PubMed          Journal:  Chem Phys        ISSN: 0301-0104            Impact factor:   2.348


  1 in total

1.  Formulation and In Vitro and In Silico Characterization of "Nano-in-Micro" Dry Powder Inhalers Containing Meloxicam.

Authors:  Petra Party; Csilla Bartos; Árpád Farkas; Piroska Szabó-Révész; Rita Ambrus
Journal:  Pharmaceutics       Date:  2021-02-03       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.